Post
proceedings video is now available to purchase online at www.postproceedings.com.
Medical schools, hospitals and biomedical research institutions
are increasing their partnerships with industry with the purposes
of bringing discoveries forward more quickly to benefit patients
and potentially providing a revenue stream to supplement research
support. In some cases, these partnerships have appeared unethical
and created public suspicion that an individual's or company's,
not the patient's, interest is really being served. These
conflicts of interest are the subject of vigorous debate.
Should these conflicts be avoided completely or managed? Can
they be managed? If yes, how can they best be managed? Who
should set the standards? "A National Dialogue on Biomedical
Conflicts of Interest and Innovation Management" brings
prominent thinkers to a common podium for a full day of exchanging
views on these and related topics. Outstanding speakers, moderators
and panelists, recognized leaders in academic biomedical research,
industry, government, medical research publishing, bioethics,
and professional medical organizations, will participate in
interactive discussions with a target audience of decision
makers from all of these communities.
Topics:
- Research, Innovation and Safety: Doing the Right Thing
- Guiding Principles: Where are We Headed?
- Applications in the Real World: Defining Boundaries and
Managing Innovation
- Conflicts, Compliance and Enforcement: Government Priorities
and Initiatives
- Guidelines and Performance: Creating a Culture of Ethics
Confirmed Speakers:
- Richard Thornburgh, Former U.S. Attorney General, Governor
of Pennsylvania and Director of a publicly traded pharmaceutical
company
- Roy Vagelos, MD, Former CEO, Merck
- Nina Totenberg, National Public Radio, Legal Affairs Correspondent
- Darrell Kirch, MD, Incoming President, AAMC
- Bernard Schwetz, DVM, PhD, Director, Office of Human Research
Protections
- Thomas Stossel, MD, Professor of Medicine, Harvard Medical
School
- Ed Soule, PhD, CPA, Associate Professor, Georgetown University
- Jeffrey Kahn, PhD, Director, Center for Bioethics, University
of Minnesota
- Philip A. Pizzo, MD, Dean, Stanford University School
of Medicine
- James Sheehan, U.S. Assistant Attorney General, Department
of Justice
- Jeffrey M. Drazen, MD, Editor in Chief, New England Journal
of Medicine
- Gail H. Cassell, PhD, D.Sc. (hon) Vice President, Scientific
Affairs and Distinguished Lilly Research Scholar for Infectious
Diseases, Eli Lilly and Company
- Paul LaViolette, COO Boston Scientific: Chairman, Special
Committee on Codes of Ethics, AdvaMed
- Norka Ruiz-Bravo, PhD, Deputy Director for Extramural
Research, National Institutes of Health
- Edward Miller, MD, Dean & CEO, Johns Hopkins University
School of Medicine
Who Should Attend:
Decision makers from biomedical research institutions, clinical
centers, industry and government.
A unique opportunity to listen to and discuss key issues
regarding innovation in contemporary biomedical research and
medicine.
With Support From:
|